CompletedPhase 1NCT02267109
Phase 1 Trial of Ebola Vaccine in Mali
Studying Ebola hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Maryland, Baltimore
- Principal Investigator
- Myron M Levine, MD, DTPHUniversity of Maryland, Baltimore
- Intervention
- Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z(biological)
- Enrollment
- 91 enrolled
- Eligibility
- 18-50 years · All sexes
- Timeline
- 2014 – 2016
Study locations (1)
- Center for Vaccine Development, Mali, Bamako, Mali
Collaborators
Wellcome Trust · National Institute of Allergy and Infectious Diseases (NIAID) · Leidos Biomedical Research, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02267109 on ClinicalTrials.govOther trials for Ebola hemorrhagic fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05992480REVIVE (Response to the Ebola Virus Vaccine)Tulane University
- ACTIVE NOT RECRUITINGPHASE2NCT06803342A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy AdultsAlbert B. Sabin Vaccine Institute
- RECRUITINGPHASE3NCT06126822Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCInstitute of Tropical Medicine, Belgium
- ACTIVE NOT RECRUITINGPHASE2NCT06100913Immunology of Ebola VaccineEmory University